S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
Chick-fil-A Is Hiring an 'Entertainment Producer'
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
Chick-fil-A Is Hiring an 'Entertainment Producer'
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
Chick-fil-A Is Hiring an 'Entertainment Producer'
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
Chick-fil-A Is Hiring an 'Entertainment Producer'
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead

Immunocore (IMCR) Stock Forecast & Price Target

$52.64
-0.09 (-0.17%)
(As of 12/1/2023 ET)
Compare
Today's Range
$51.82
$53.22
50-Day Range
$42.85
$52.73
52-Week Range
$42.21
$67.43
Volume
367,414 shs
Average Volume
351,232 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.62

Immunocore Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 14 Analyst Ratings

Analysts' Consensus Price Target

$74.62
41.75% Upside
High Forecast$91.00
Average Forecast$74.62
Low Forecast$16.00
TypeCurrent Forecast
12/2/22 to 12/2/23
1 Month Ago
11/2/22 to 11/2/23
3 Months Ago
9/3/22 to 9/3/23
1 Year Ago
12/2/21 to 12/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$74.62$72.29$74.62$79.00
Predicted Upside41.75% Upside29.68% Upside32.68% Upside50.87% Upside
Get Immunocore Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.


IMCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunocore Stock vs. The Competition

TypeImmunocoreMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside41.75% Upside645.70% Upside2,867.38% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$60.00+27.82%
11/2/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
10/31/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$84.00+91.87%
9/21/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$75.00 ➝ $85.00+71.72%
9/13/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$75.00+38.84%
8/23/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$90.00+50.23%
8/16/2023Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$84.00+39.42%
8/11/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$85.00 ➝ $91.00+48.89%
7/31/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$79.00+20.45%
7/17/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$67.00+5.68%
5/11/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$70.00 ➝ $74.00+23.62%
3/30/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$85.00+77.60%
3/24/2023Bryan, Garnier & Co
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$16.00-66.22%
12/16/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$33.00 ➝ $80.00+34.63%
(Data available from 12/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IMCR Price Target - Frequently Asked Questions

What is Immunocore's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Immunocore stock is Moderate Buy based on the current 1 hold rating and 13 buy ratings for IMCR. The average twelve-month price prediction for Immunocore is $74.62 with a high price target of $91.00 and a low price target of $16.00. Learn more on IMCR's analyst rating history.

Do Wall Street analysts like Immunocore more than its competitors?

Analysts like Immunocore more than other Medical companies. The consensus rating score for Immunocore is 2.93 while the average consensus rating score for medical companies is 2.67. Learn more on how IMCR compares to other companies.

Is Immunocore being upgraded by Wall Street analysts?

Over the previous 90 days, Immunocore's stock had 1 upgrade by analysts.

Does Immunocore's stock price have much upside?

According to analysts, Immunocore's stock has a predicted upside of 36.08% based on their 12-month stock forecasts.

What analysts cover Immunocore?

Immunocore has been rated by Cantor Fitzgerald, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, and Robert W. Baird in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:IMCR) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -